News items 2.5 million Euros for cancer research

15 April 2021

The Radboudumc receives 2.56 million Euros from the Dutch Cancer Society (KWF) for three studies to ensure oncological progress during COVID-19. The projects that have been awarded focus on innovative research into ovarian cancer and groundbreaking immunotherapy.

Preventing Hereditary Ovarian Cancer - Joanne de Hullu

Women with an inherited error in the genes BRCA1 or BRCA2 have a greatly increased risk of ovarian cancer. They are advised to have their fallopian tubes and ovaries removed. This procedure is very effective, reducing the risk of ovarian cancer by 80-96%, but ovarian removal also leads to early menopause, with all its adverse consequences.
Joanne de Hullu, gynecologist, is investigating whether it is safe to remove the fallopian tubes (the presumed origin of ovarian cancer) first and only later the ovaries. The results of her previous KWF research show that this improves quality of life, especially in terms of menopausal symptoms and sexual functioning. 
In a large international study, Joanne de Hullu is now going to further map the risks. Together with nine other countries, she is investigating how often ovarian cancer occurs in women who opted for the new approach and what their quality of life is like. De Hullu hopes to show that the risk of ovarian cancer remains the same, but that patients experience a much better quality of life.

Improving immunotherapy - Harry Dolstra and Gosse Adema

There are also two studies that focus on immunotherapy. This research focuses on a groundbreaking treatment that helps the patient's immune system to clear cancer cells on its own. 
Harry Dolstra, associate professor at the Laboratory of Hematology, is working on immunotherapy for ovarian cancer using 'natural killer' cells. He is investigating the possibility of growing these types of immune cells in large quantities so that they can be injected directly, rather than small amounts for each patient individually. In addition, these "natural killer" cells are equipped with a CAR (chimeric antigen receptor), which serves as a kind of "grappler'' that enables them to better recognize and clear cancer cells. 

Gosse Adema professor of molecular immunology in the Radiotherapy & Oncoimmunology (ROI) laboratory of the Department of Radiotherapy, is researching sialic acids and their receptors. Sialic acids are sugars that cancer cells produce in increased amounts to protect themselves from attacks by the immune system. Gosse Adema is investigating whether the effect of immunotherapy can be improved by blocking these sialic acids or their receptors on immune cells.

The awards are part of the latest round of funding from KWF, in which more than 30 million Euros will be awarded to Dutch cancer research.

Related news items

Tailored drug dosage for pregnant women

14 March 2022 Three quarters of women in the Netherlands use some form of medication during pregnancy, but little is known about the appropriate dosages. Research by the Radboudumc, MUMC+ and Lareb Mothers of Tomorrow should change this. read more

Ioannis Sechopoulos receives NWO Vici grant for research on improving breast cancer diagnostics

1 March 2022 Ioannis Sechopoulos will conduct research into improving tomosynthesis, an X-ray examination that radiologists use to detect breast cancer. read more

Tackling cancer with radioactive particles

2 September 2021 Professor Sandra Heskamp receives grant for research into cancer treatment with radioactivity read more

VIDI grants for researchers of Radboud university medical center

14 July 2021 Several Radboudumc researchers have been awarded a VIDI grant by the Dutch Organisation for Scientific Research (NWO). They each receive a sum of 800,000 euros, which they will use over the next five years to develop their own innovative line of research and to set up a research group. read more

New culture method reveals how cancer cells bypass immune system

5 July 2021 Publication in Cancer Immunology Research read more

New method to prevent ovarian cancer increases quality of life

8 June 2021 Researchers at Radboudumc have shown that quality of life is better in women with a BRCA1 or BRCA2 mutation after fallopian tube removal with delayed ovarian removal to prevent ovarian cancer. read more